TRIQUILAR 28 TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

LEVONORGESTREL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL; ETHINYL ESTRADIOL; LEVONORGESTREL

Sẵn có từ:

BAYER INC

Mã ATC:

G03AB03

INN (Tên quốc tế):

LEVONORGESTREL AND ESTROGEN

Liều dùng:

125MCG; 30MCG; 40MCG; 50MCG; 30MCG; 75MCG

Dạng dược phẩm:

TABLET

Thành phần:

LEVONORGESTREL 125MCG; ETHINYL ESTRADIOL 30MCG; ETHINYL ESTRADIOL 40MCG; LEVONORGESTREL 50MCG; ETHINYL ESTRADIOL 30MCG; LEVONORGESTREL 75MCG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

28

Loại thuốc theo toa:

Prescription

Khu trị liệu:

CONTRACEPTIVES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0618648001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2007-03-08

Đặc tính sản phẩm

_TRIQUILAR Product Monograph _
_Page 1 of 54_
PRODUCT MONOGRAPH
PR
TRIQUILAR
® 21
PR
TRIQUILAR
® 28
0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
0.075 mg levonorgestrel and 0.04 mg ethinyl estradiol tablets
0.125 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
USP
Oral Contraceptive
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
May 26, 2017
Submission Control No: 202824
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc
_TRIQUILAR Product Monograph _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................23
OVERDOSAGE
................................................................................................................26
ACTION AND CLINICAL PHARMACOLOGY
............................................................27
STORAGE AND STABILITY
..........................................................................................30
SPECIAL HANDLING INSTRUCTIONS
.......................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
.....................................